TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05093673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal Cerebellar tDCS
Description: 2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantic Feature Analysis (SFA)
Description: Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Semantic Feature Analysis (SFA)
Description: Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
Study: NCT05996562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Artery Denervation
Description: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55°C for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.
Study: NCT04917471

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beet root juice
Description: 70 ml bid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: 70 ml bid
Study: NCT06421636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06502171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib Oral Tablet
Description: Cabozantinib will be taken once a day. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 20 mg.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.~Cabozantinib may be taken simultaneously with selumetinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Oral Capsule
Description: Selumetinib will be taken twice a day, at least 6 hours apart. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 15 mg twice a day.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.
Study: NCT04938193

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-citrate PET/CT
Description: PET/CT Imaging with 68Ga-citrate PET/CT injection
Study: NCT05516758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peresolimab
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peresolimab
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peresolimab
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05316753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioversion with a pulsed biphasic waveform
Description: Cardioversion with a pulsed biphasic waveform

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion with a biphasic truncated exponential waveform
Description: Cardioversion with a biphasic truncated exponential waveform
Study: NCT05464641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxford knee score
Description: The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxford knee score
Description: The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse
Study: NCT05754944

Intervention type: DIAGNOSTIC_TEST
Intervention: ABI/TBI
Description: ABI/TBI to be performed after surgery while patient is still admitted at the hospital.
Study: NCT05089760

Intervention type: OTHER
Intervention: No intervention
Description: This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.
Study: NCT06205004

Intervention type: OTHER
Intervention: Questionnaires
Description: In the present study, the investigators aim to investigate the prevalence and effects of IA on the psychosocial well-being among adults in Hong Kong by measuring the level of Internet use, depression, anxiety, sleep quality, QOL together with basic demographic data in the current situation of COVID with popularity of Metaverse.
Study: NCT05743946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trikafta
Description: Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
Study: NCT05754944

Intervention type: OTHER
Intervention: Questionnaires
Description: PAD symptoms questionnaire to be administered at baseline before surgery. mLEFS (included in PAD symptoms questionnaire) and WIQ to be administered at baseline before surgery. mLEFS and WIQ will be administered 1 month, 3 months, 6 months after surgery and every 6 months after that for a goal of at least 1 year.
Study: NCT05175521

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eucalyptus Oil Scent
Description: Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isopropyl Alcohol Vapors
Description: Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
Study: NCT04771130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous or subcutaneous administration for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous or subcutaneous administration for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous or subcutaneous administration for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Oral administration for 8 days on second cycle only.
Study: NCT05907954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darovasertib
Description: Oral, potent, selective inhibitor of Protein Kinase C
Study: NCT06435364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimilation
Description: This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear. Somatosensory innervation is provided by the auricular branch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy is mostly defined by the tissue targeted by the practitioner; it can be joint biased, muscle and connective tissue biased and/or neurovascular system biased techniques.
Study: NCT05762250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
Study: NCT06324422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Description: Participants in this arm are randomized to perform 12 weeks of supervised high intensity progressive aerobic exercise comprising continuous and/or interval cycling-, rowing- or cross-trainer sessions, increasing from 30 minutes towards 60 minutes with intensity increasing from 65 to 90% of individual maximum heart rate. The 12 weeks of aerobic exercise are followed by 12 weeks of habitual lifestyle (follow up period).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise intervention
Description: Participants in this arm are randomized to a 24-week waitlist control group. The control group will continue their habitual lifestyle throughout the 24 weeks. After 24 weeks, the waitlist control group will begin a 12 week supervised resistance exercise intervention comprising machine exercises in 3 to 5 sets with 2-3 minutes rest in between and a decrease from 12 to 6 repetitions in parallel with intensity increasing from 15RM (repetition maximum) to 8 RM.
Study: NCT04771130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Oral administration for 28 days on a 28-day cycle.
Study: NCT06393517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 IR (Formulation 1)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 IR (Formulation 1)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
Study: NCT04771130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Oral administration for 10, 14 or 21 days on a 28-day
Study: NCT06443502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant Antibiotic Therapy
Description: Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.
Study: NCT05590455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection
Description: one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids
Study: NCT06185413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participatory system dynamics approach
Description: First, local health profiles of children will be collected and used to engage key leaders and stakeholders from intervention communities and municipal administrations in participatory processes. These will be used to develop a systems map of drivers of PA behaviour in schoolchildren aged 6-12 years in the local communities. Second, based on the systems map, stakeholders from the civic and private sectors will be involved in developing and implementing actions to promote healthy PA behaviour through system changes.
Study: NCT05227027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game Module
Description: Receive access to the the game module through the free, 'Smoke Free' smartphone application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoke Free smartphone application
Description: Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free smartphone application
Description: Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
Study: NCT05779098

Intervention type: PROCEDURE
Intervention: Extensive hepatectomy
Description: Extensive hepatectomy
Study: NCT06048380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil
Description: Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline eye drops
Study: NCT05035225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Multiple Pharmacy Use Survey
Study: NCT05278780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for eligibility
Description: Asynchronous screening
Study: NCT05925101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction-only condition
Description: In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).
Study: NCT04811989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructive video on diabetic foot care
Description: In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
Study: NCT05925101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction-only condition
Description: In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate-drop condition
Description: In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate-drop condition
Description: In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.
Study: NCT04811989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informative leaflet with real-time guided reading
Description: The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informative leaflet to read at home
Description: Patients receive a leaflet about diabetic foot care to read at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face teaching
Description: Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face teaching
Description: Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
Study: NCT05925101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate-hold condition
Description: In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnitude-drop condition
Description: In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR according to a VI 1.5-s schedule, but we will deliver the reinforcer for just 6 s each time. This change from delivering 60 s of access to the functional reinforcer following destructive behavior in baseline to delivering 6 s of reinforcer access for the FCR during FCT will produce a large reduction in the magnitude of reinforcement relative to baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnitude-hold condition
Description: This condition will be identical to the magnitude-drop condition except that we will deliver 60 s of access to the functional reinforcer contingent on the FCR, so that the magnitude of reinforcement will equal that delivered in baseline for destructive behavior. To ensure that the magnitude of reinforcement does not drop in the magnitude-hold condition, we will yoke the rate and timing of reinforcer deliveries for the FCR during FCT to the rate and timing of reinforcer deliveries for destructive behavior in baseline.
Study: NCT04811989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face teaching
Description: Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
Study: NCT05660772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfragmented Adipose Tissue
Description: Microfragmented Adipose Tissue derived using Lipogems® Kit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: intra-articular knee injection of corticosteroid
Study: NCT05284149

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hirsutella Sinensis Nutrient Supplements
Description: This randomized control study will be conducted in 2 years. We expect to recruit 50 participants with age ≥ 50 years old. Enrolled participants will be recruited into Hirsutella Sinensis nutrient supplement group (50 patients H.S. suppl.) . The medication will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving Hirsutella Sinensis nutrient supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We expect to recruit 50 placebo participants with age ≥ 50 years old. This randomized control study will be conducted in 2 years. The placebo will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving placebo.
Study: NCT05925101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality-drop condition
Description: In this condition, we will place destructive behavior on extinction and deliver the reinforcer from the paired-choice assessment that the participant chooses approximately 1/12th as often as the highest preference stimulus from that assessment. This change from the most preferred stimulus from the paired-choice assessment to one chosen 1/12th as often will constitute a large drop in the quality of reinforcement during FCT relative to baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality-hold condition
Description: We will place destructive behavior on extinction and deliver the most preferred reinforcer from the paired-choice assessment on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline in this condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate-drop/quality-increase condition
Description: In this condition, we will program the same large drop in reinforcement by delivering reinforcement on a VI 15-s schedule, but we also will increase reinforcement quality by simultaneously delivering the highest quality reinforcer identified during a competing stimulus assessment. We will use the competing stimulus assessment in Ex 4 because it directly assesses the quality of alternative reinforcement relative to the quality of the reinforcer for destructive behavior, whereas the paired-choice assessment could not guarantee that the selected stimulus would be of a higher quality than the reinforcer for destructive behavior.
Study: NCT05911230

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Advanced diffusion-weighted MRI (ADW-MRI)
Description: An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.
Study: NCT04386980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Resiniferatoxin is a compound purified from natural sources.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent in normal saline